Small Molecule Activators for Procaspase-3 in Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Cancer cells often resist natural apoptotic signals due to alterations in key proteins within the apoptotic cascade, making it challenging for existing therapeutics to induce programmed cell death, especially in cells with mutations downstream of targeted proteins.
Innovation Solution
Development of small molecules that directly activate procaspase-3, a downstream effector in the apoptotic cascade, to induce apoptosis in cancer cells, even those with defective apoptotic machinery, by interacting with the procaspase-3 molecule to overcome the safety catch mechanism and facilitate its conversion to active caspase-3.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapeutics target upstream proteins in the apoptotic cascade (such as p53, Bcl family proteins, or IAP family proteins), then apoptosis can be induced in some cancer cells, but cancer cells with mutations downstream of these proteins remain resistant to treatment
Solution Approach 1:
Instead of targeting upstream proteins in the apoptotic cascade (conventional approach), the invention inverts the strategy by directly activating downstream executioner caspases (caspase-3 and caspase-7). This reversal ensures effectiveness regardless of upstream pathway mutations, as the activation occurs at the terminal effector stage that is common to all apoptosis-resistant cancer cells.
Solution Approach 2:
The invention employs small molecule compounds as intermediaries that directly bind to and activate procaspase-3 and procaspase-7. These compounds serve as direct activators that bridge the gap between apoptotic signaling and execution, bypassing the need for intact upstream signaling pathways while still achieving effective apoptosis induction.
2Productivity
If small molecules target early positions in the apoptotic cascade (such as p53 or Bcl family proteins), then therapeutic activity is achieved, but cancers with mutations in downstream proteins can still resist the beneficial effects
Solution Approach 1:
The invention extracts the essential apoptotic function from the complex upstream signaling pathway and concentrates it at the downstream executioner stage. By isolating the critical activation step to procaspase-3 and procaspase-7, the therapy achieves reliable apoptotic effect regardless of the integrity of upstream components, effectively removing the dependency on upstream pathway functionality.
3Reliability
If procaspase-3 is blocked by the safety catch mechanism, then premature activation is prevented, but the cell cannot undergo apoptosis when needed
Solution Approach 1:
The invention converts the harmful effect of the safety catch mechanism (which prevents premature activation) into a beneficial selective activation system. The small molecule compounds specifically overcome the safety catch barrier in a controlled manner, allowing procaspase-3 activation only when therapeutic intervention is intended, thereby transforming the safety mechanism into a controlled release system for apoptosis induction.
Data Source
AI summary
Compositions and methods relating to induction of cell death such as in cancer cells are disclosed. Compounds and related methods for synthesis and use thereof, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells are disclosed. Compounds in connection with modification of procaspases such as procaspase-3 are disclosed. In various embodiments, the compounds and compositions are capable of activation of procaspase-3.